Wright Medical Group, Inc. CVR (WMGIZ)

[fredman]

Earnings release (Annual Report) and conference call is scheduled for February 25th. The tender offer should be priced somewhere in the range of $5.75 to $6.00, as the revenue milestones are based upon GLOBAL sales of Biomimetic products, imo.

"“Product” means any of the following medical products: (a) AUGMENT Bone Graft; (b) AUGMENT Injectable; (c) AUGMATRIX Bone Graft; (d) AUGMENT Chronic Tendinopathy; or (e) any other medical product that the Company, in its sole discretion, elects to offer for sale in any jurisdiction and that: (i) contains recombinant human platelet-derived growth factor BB; and (ii) is covered by patents or utilizes proprietary know-how that was owned or controlled by Achilles immediately prior to the execution of this CVR Agreement."

Source: http://www.lawinsider.com/contracts/5JXznltiLGu57a6ucWWJPJ/wright-medical-group-inc/contingent-value-rights-agreement/2013-03-01

The CVR Agreement does not prohibit Wright or any of its subsidiaries or affiliates from acquiring the CVRs, whether in open market transactions, private transactions or otherwise. However, prior to any acquisition of CVRs, Wright must publicly disclose the amount of CVRs which it has been authorized to acquire and Wright must report in each of its annual and quarterly reports the amount of CVRs it has been authorized to acquire as well as the amount of CVRs it has acquired as of the end of the quarterly or annual period reported in such quarterly or annual report.

Source: http://www.nasdaqtrader.com/content/newsalerts/2013/infocircular/WMGIZcircular.pdf